Status:
RECRUITING
Myeloma Novel Drug Discovery Ver 1.2
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborating Sponsors:
Royal Marsden NHS Foundation Trust
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with few...
Eligibility Criteria
Inclusion
- Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment
- Participants aged 18 years of age or above
- Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Exclusion
- Participants unable to provide consent
- Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Key Trial Info
Start Date :
July 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2035
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05968417
Start Date
July 22 2020
End Date
February 28 2035
Last Update
August 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom, SM25PT